Aeglea BioTherapeutics buys Spyre Therapeutics to revolutionize IBD treatment
Aeglea BioTherapeutics, a Nasdaq-listed company, has acquired Spyre Therapeutics, a private biotech company dedicated to advancing a promising pipeline of antibody therapeutics aimed at revolutionizing ... Read More
Lilly to acquire biopharma company DICE Therapeutics in $2.4bn deal
Eli Lilly and Company (Lilly) has agreed to acquire US-based biopharmaceutical company DICE Therapeutics, listed on the Nasdaq, in an all-cash deal worth $2.4 billion. ... Read More
Novartis to expand renal portfolio with Chinook Therapeutics acquisition
Novartis has announced its agreement to acquire Chinook Therapeutics, a clinical stage biopharmaceutical company based in Seattle, Washington in a deal worth up to around ... Read More
Indoco Remedies to acquire 85% stake in Florida Pharmaceutical Products
In a strategic move to strengthen its presence in the United States pharmaceutical market, Indoco Remedies, an Indian pharma company, has agreed to acquire an ... Read More
Laurus Labs expands stake in Immunoadoptive Cell Therapy for Rs.80cr
Hyderabad-based pharmaceutical company Laurus Labs has announced a significant investment in Immunoadoptive Cell Therapy (lmmunoACT), an advanced cell and gene therapy firm. The deal, valued ... Read More
Ironwood Pharmaceuticals to acquire Swiss biotech company VectivBio
Ironwood Pharmaceuticals, a gastrointestinal (GI)-focused healthcare company, has agreed to acquire VectivBio Holding AG, a Switzerland-based biotech company, listed on the Nasdaq, for around $1 ... Read More
Lupin to acquire French generics injectables developer Medisol
Indian pharma company Lupin has agreed to acquire Medisol, a French pharmaceutical company, for an undisclosed price. Established in 2011, Medisol is engaged in developing ... Read More
Astellas Pharma to acquire avacincaptad pegol developer Iveric Bio for $6bn
Japanese pharma company Astellas Pharma has agreed to acquire Nasdaq-listed Iveric Bio in an all-cash deal worth around $5.9 billion with an aim to create ... Read More
Lilly to sell hypoglycemia drug BAQSIMI to Amphastar Pharmaceuticals
Eli Lilly and Company (Lilly) has agreed to sell its severe hypoglycemia drug BAQSIMI to Amphastar Pharmaceuticals in a deal potentially worth up to $1.07 ... Read More
GSK to acquire Canadian biopharma company BELLUS Health for $2bn
GSK has agreed to acquire BELLUS Health, a Canadian biopharma company, in a deal worth around $2 billion in a move to further bolster its ... Read More